- Home
- AEVA vs GYRE Comparison
AEVA vs GYRE Comparison
Compare AEVA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- GYRE
- Stock Information
- Founded
- AEVA 2019
- GYRE 2002
- Country
- AEVA United States
- GYRE United States
- Employees
- AEVA N/A
- GYRE N/A
- Industry
- AEVA Auto Parts:O.E.M.
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- GYRE Health Care
- Exchange
- AEVA Nasdaq
- GYRE Nasdaq
- Market Cap
- AEVA 808.6M
- GYRE 897.1M
- IPO Year
- AEVA N/A
- GYRE N/A
- Fundamental
- Price
- AEVA $13.18
- GYRE $7.19
- Analyst Decision
- AEVA Buy
- GYRE
- Analyst Count
- AEVA 6
- GYRE 0
- Target Price
- AEVA $20.80
- GYRE N/A
- AVG Volume (30 Days)
- AEVA 2.8M
- GYRE 76.7K
- Earning Date
- AEVA 07-31-2025
- GYRE 08-19-2025
- Dividend Yield
- AEVA N/A
- GYRE N/A
- EPS Growth
- AEVA N/A
- GYRE N/A
- EPS
- AEVA N/A
- GYRE 0.02
- Revenue
- AEVA $13,825,000.00
- GYRE $100,643,000.00
- Revenue This Year
- AEVA $94.59
- GYRE $21.04
- Revenue Next Year
- AEVA $127.05
- GYRE $89.64
- P/E Ratio
- AEVA N/A
- GYRE $89.64
- Revenue Growth
- AEVA 111.39
- GYRE N/A
- 52 Week Low
- AEVA $2.36
- GYRE $6.11
- 52 Week High
- AEVA $38.80
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- AEVA 29.75
- GYRE 46.35
- Support Level
- AEVA $12.28
- GYRE $6.70
- Resistance Level
- AEVA $23.42
- GYRE $7.47
- Average True Range (ATR)
- AEVA 1.87
- GYRE 0.37
- MACD
- AEVA -1.19
- GYRE 0.02
- Stochastic Oscillator
- AEVA 6.11
- GYRE 46.97
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.